InvestorsHub Logo
Followers 34
Posts 1811
Boards Moderated 0
Alias Born 03/26/2014

Re: CoolG73 post# 9535

Monday, 11/25/2019 8:59:57 AM

Monday, November 25, 2019 8:59:57 AM

Post# of 17564
From what I recall from CCs post P2 trials, the company was excited that P3 was going to be patients who live in better conditions so less outside variables will affect them.
It sounded quite promising given that they yielded such good results with such a difficult case group in P2.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AUPH News